Welcome to our dedicated page for Aura Biosciences news (Ticker: AURA), a resource for investors and traders seeking the latest updates and insights on Aura Biosciences stock.
Aura Biosciences, Inc. develops precision therapies for solid tumors designed to preserve organ function. The clinical-stage biotechnology company’s recurring updates center on bel-sar (AU-011), its lead candidate in late-stage development for early choroidal melanoma and in early-stage development for other ocular oncology indications and bladder cancer.
Company news also covers financial results, clinical-program business highlights, investor conference participation, executive leadership changes, and capital actions involving common stock and pre-funded warrants. Aura’s disclosures frequently connect pipeline progress with oncology indications, trial activity, liquidity planning, and governance developments.
Aura Biosciences (NASDAQ: AURA) reported Q4 and full-year 2025 results and program updates on March 30, 2026.
Key points: CoMpass Phase 3 enrollment now expected complete by mid-2026 with topline data in 2H 2027; Phase 1b/2 NMIBC initial 3-month data expected mid-2026; new formulation achieved 12-month stability for non-ocular solid tumors and a patent application was filed; cash and marketable securities totaled $144.2M, funding operations into Q1 2027.
Aura Biosciences (NASDAQ: AURA) said senior management will participate in three investor conferences in March 2026 with live fireside chats and webcasts. Events include TD Cowen on March 4, Leerink Partners on March 10, and Citizens Life Sciences on March 11.
Live webcasts will be available on the company's Investors & Media page and replays will be archived for 90 days after each presentation.
Aura Biosciences (NASDAQ: AURA) will participate in the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025. CEO Elisabet de los Pinos, PhD, will appear in a fireside chat at 10:50 a.m. ET. A live webcast will be available on the company’s Investors & Media Events & Presentations page and a replay will be archived for 90 days following the presentation.
This presentation provides an investor update opportunity with company leadership and a public webcast for remote access.
Aura Biosciences (NASDAQ: AURA) reported Q3 2025 results and clinical updates on Nov 13, 2025. The company now expects to complete enrollment in its global Phase 3 CoMpass trial in 2026 with topline data for the 15-month primary endpoint in Q4 2027. The Phase 1b/2 NMIBC trial remains on track with initial three-month data expected in mid-2026. Phase 1 immune-profiling showed de novo mature tertiary lymphoid structures in 3/5 patients and increases in NK and T-cell densities (NK up to 40x, CD4+ cytolytic up to 7x).
Financials: cash and marketable securities of $161.9M as of Sept 30, 2025, funding operations into the first half of 2027. R&D expense rose to $22.2M (Q3 2025) and net loss was $26.1M for the quarter.
Aura Biosciences (NASDAQ: AURA), a clinical-stage biotech company focused on developing precision therapies for solid tumors, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
The company's CEO, Elisabet de los Pinos, PhD, will deliver a presentation on September 10, 2025, at 11:00 a.m. ET. Investors can access the live webcast through Aura's investor relations website, where it will remain available for replay for 90 days after the presentation.
Aura Biosciences (NASDAQ: AURA) reported Q2 2025 financial results and clinical progress updates. The company strengthened its financial position with a $75 million equity financing, extending cash runway into H1 2027. Current cash position stands at $177.3 million.
Key clinical developments include the ongoing global Phase 3 CoMpass trial in early choroidal melanoma, with over 240 patients registered for pre-screening and expected completion by end of 2025. The company is also advancing a Phase 1b/2 trial in non-muscle invasive bladder cancer (NMIBC) and expanding its ocular oncology program to include metastases to the choroid and cancers of the ocular surface.
Q2 2025 financials showed increased R&D expenses of $22.9 million (vs $16.9M in Q2 2024) and slightly decreased G&A expenses of $5.7 million (vs $5.9M in Q2 2024). Net loss widened to $27.0 million compared to $20.3 million in Q2 2024.
Aura Biosciences (NASDAQ: AURA) has announced the pricing of a public offering expected to raise $75.0 million in gross proceeds. The offering consists of:
- 11,735,565 shares of common stock with warrants to purchase 2,933,891 additional shares
- Pre-funded warrants to purchase 3,571,435 shares (exercise price: $0.00001) with warrants to purchase 892,858 additional shares
The combined offering price is $4.90 per share of common stock and accompanying warrant, while pre-funded warrants are priced at $4.89999. The accompanying warrants have a 5-year term with a $4.90 exercise price. Proceeds will fund clinical programs in early-stage choroidal melanoma, metastases to the choroid, ocular surface cancers, and non-muscle invasive bladder cancer.
Aura Biosciences (NASDAQ: AURA), a clinical-stage biotech company focused on precision therapies for solid tumors, has announced a proposed public offering of common stock and warrants. The offering includes shares of common stock, warrants to purchase common stock, and pre-funded warrants with accompanying common stock warrants.
The offering will be managed by Leerink Partners and Evercore ISI as joint bookrunning managers, with LifeSci Capital as an additional bookrunning manager. Citizens Capital Markets and Scotiabank are serving as co-managers. The offering will be conducted under a shelf registration statement that was declared effective by the SEC on April 5, 2024.
Aura Biosciences (NASDAQ: AURA) reported Q1 2025 financial results and key developments. The company's lead candidate bel-sar is advancing in multiple clinical trials. The global Phase 3 CoMpass trial for early-stage choroidal melanoma has registered over 220 patients for pre-screening, with potential enrollment completion by end of 2025. The company also enrolled its first patient in a Phase 1b/2 trial for non-muscle-invasive bladder cancer (NMIBC), with initial data expected by year-end 2025.
Financial highlights include cash position of $128.0 million, expected to fund operations into H2 2026. Q1 2025 saw increased R&D expenses of $23.3 million (vs $17.1M in Q1 2024) and net loss of $27.5 million (vs $19.7M in Q1 2024). The company strengthened its leadership by appointing Tony Gibney as CFO and Business Officer.
Aura Biosciences (NASDAQ: AURA), a clinical-stage biotech company focused on developing precision therapies for solid tumors, has announced its participation in three upcoming investor conferences in May 2025:
- The Citizens Life Sciences Conference - Fireside Chat on May 8, 2025, at 9:30 a.m. ET
- H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ - Fireside Chat on May 20, 2025, at 2:00 p.m. ET
- TD Cowen 6th Annual Oncology Innovation Summit - Fireside Chat on May 27, 2025, at 10:00 a.m. ET
Live webcasts will be available on the company's investor relations website, with replays accessible for 90 days after each presentation.